Sevasemten: Servier provides update on studies in Duchenne and Becker muscular dystrophy Servier has announced that it will discontinue the …
Sevasemten: Servier provides update on studies in Duchenne and Becker muscular dystrophyRead More

17 November 2026 by Lizzie Cox
Sevasemten: Servier provides update on studies in Duchenne and Becker muscular dystrophy Servier has announced that it will discontinue the …
Sevasemten: Servier provides update on studies in Duchenne and Becker muscular dystrophyRead More
11 November 2026 by Lizzie Cox
Roche and Sarepta Update on ELEVIDYS Study This week Roche and Sarepta Therapeutics have shared updates on the ongoing development programme …

11 November 2026 by Katie Endacott
On 3rd November, Servier announced the Phase 3 GRAND CANYON clinical trial of sevasemten in people living with Becker muscular dystrophy (BMD) did not …
Sevasemten: Servier shares Clinical Trial Results in Becker Muscular DystrophyRead More

11 November 2026 by Katie Endacott
On 5 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) published interim advice for healthcare professionals and families …
Givinostat (Duvyzat®): MHRA Shares Interim Monitoring Advice Read More
19 August 2026 by John Marrin
Entrada Therapeutics has released its latest quarterly update on its Duchenne clinical trial programmes. Below, we've summarised what's new for each …

16 July 2026 by Lizzie Cox
Science Education Workshops: Decoding Duchenne Together This Summer our fun filled family days will also offer you the opportunity to …
Science Education Workshops: Decoding Duchenne TogetherRead More
16 July 2026 by Lizzie Cox
Halfway Through Action Duchenne’s Webinar Series 2026: Learning, Connecting and Growing Together "The support our family has received from …
7 July 2026 by John Marrin
Solid Biosciences has shared an update on SGT-003, its investigational gene therapy for Duchenne muscular dystrophy (DMD), coinciding with …
Solid Biosciences Shares Update on SGT-003 Duchenne Gene Therapy ProgrammeRead More
1 July 2026 by Lizzie Cox
We're Recruiting: Director of Services and Safeguarding Welcome to Action Duchenne “Your child has Duchenne Muscular …
We’re Recruiting: Director of Services and SafeguardingRead More
8 June 2026 by John Marrin
The Scottish Medicines Consortium (SMC) has completed a reassessment of Translarna (ataluren) and has decided not to recommend it for routine use …
Translarna (Ataluren) Not Accepted for Continued Use Under NHSScotlandRead More

5 June 2026 by Victoria Edwards
“I just want to say that Victoria and the rest of the Action Duchenne family are incredible human beings. The support they give is amazing. When you …
Make a real difference with our amazing events and challengesRead More

20 May 2026 by John Marrin
Entrada Therapeutics has shared its latest quarterly update across all four of its active Duchenne programmes. For families in the UK, there are …
Entrada Therapeutics Provides Quarterly Update on ELEVATE Studies. Read More
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
